Assistive Tech: Restoring Abilities, Lives
Assistive technologies, like brain implants that turn thoughts into computer commands, can restore some independence to people with severe paralysis, but are still in early trials.
Topics: science, technology, individual and values
Example
On 19 July 2022, doctors at Mount Sinai in New York gave the first US patient Synchron's Stentrode, a brain-computer interface placed through a blood vessel in the neck, so no open-brain surgery is needed. It reads movement signals from the brain so a person with severe paralysis can text, email or shop online by thought. This was part of the COMMAND safety trial approved by the US Food and Drug Administration; an earlier Australian trial found the device safe in four patients over 12 months.
Key facts
- The first US patient received Synchron's Stentrode at Mount Sinai in New York on 19 July 2022, in the FDA-approved COMMAND trial.
- The Stentrode is placed through the jugular vein, avoiding open-brain surgery, and lets patients control digital devices by thought.
- Synchron's earlier Australian SWITCH trial found the device safe in four patients over 12 months.
Limitations
- These are small early trials with a handful of patients; the device is not an approved treatment, and long-term safety and cost are unknown.
Evaluations
science evaluation
Support
Placing the electrode through a blood vessel rather than opening the skull is a scientific advance that lowers surgical risk, making brain implants thinkable for more patients.
Counterargument
Signals read from inside a vessel are weaker than those from electrodes in brain tissue, so the device offers slower control than more invasive rivals.
Rebuttal
For someone who cannot move at all, slower but safer control may be the better trade, which is why both approaches are being tested.
Additional support
The COMMAND trial ran under the first FDA exemption for a permanently implanted brain-computer interface, a step towards regulated medical use.
technology evaluation
Support
The case shows technology turning brain activity into ordinary digital actions such as texting, linking a medical device to everyday apps.
Counterargument
Users depend on the company for software updates and support; if a start-up fails, patients may be left with an implant nobody maintains.
Rebuttal
That risk argues for regulation of long-term support, not against the technology, since the benefit to users can be large.
Additional support
Trials in Australia and the US mean the device is being tested in more than one health system, helping show whether it works beyond one hospital.
individual and values evaluation
Support
For people with paralysis, being able to email or shop without a carer restores privacy and dignity, which is the core value of assistive technology.
Counterargument
Brain data is the most personal data there is, and trial users must trust a company with signals from their own minds.
Rebuttal
Strong consent rules and limits on data use can protect patients while still letting them choose the independence the device offers.
Additional support
Participants volunteer for unproven trials partly to help future patients, showing an altruism that sits alongside the personal benefit.
Sources
- NeuroNews International (2022-07-28): First US Stentrode implant heralds new field in neurointerventional surgery